Compare Carparts.Com Inc (PRTS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carparts.Com Inc vs Summit Therapeutics Inc — how do they compare? Carparts.Com Inc trades at $8.61 (market cap $66.42M), while Summit Therapeutics Inc trades at $17.3 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 206.4× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carparts.Com Inc for 45 Days and Summit Therapeutics Inc for 16 Days on average.
| PRTS | SMMT | |
|---|---|---|
Market Cap | $66.42M | $13.71B |
Volume | 40,287 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $26.38 |
52-Week Low | $3.88 | $12.43 |
Typical Hold Time | 45 Days | 16 Days |
Enterprise Value | $79.39M | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarParts.com (PRTS) trades at $8.695, up 0.99% on the day, with a bullish technical outlook supported by positive moving average signals. The company shows improving quarterly earnings performance, beating estimates in recent quarters, though it remains unprofitable with negative margins. Analyst sentiment is positive with 60% buy ratings, while recent news highlights the company's data-driven competitive strategy in the auto parts e-commerce sector.
The stock presents a speculative opportunity given its low P/S ratio of 0.11 and consistent earnings beats, but faces significant fundamental challenges including negative cash flow, declining revenue trends, and persistent losses. Key risks include execution challenges in achieving profitability and competitive pressures in the online auto parts market.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
